Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

246.27 +2.76 (+1.13%)
Official Closing Price Updated: 7:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports Second-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories ↗
 
Via Benzinga
News headline image
Bio-Rad Laboratories: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
S&P 500 Ends First Half Shy Of All-Time Highs. Here Are The Leaders And Laggards — And 5 Stocks That Could Outperform In Next 6 Months ↗
The market's resilient run has made traders cautious of a potential correction, but analysts remain optimistic about its trajectory. 
Via Benzinga
Topics Stocks
OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Via AB Newswire
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For... 
Via TheNewswire.com
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Preview: Bio-Rad Laboratories's Earnings ↗
 
Via Benzinga
News headline image
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
BIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024 ↗
BIO stock results show that Bio-Rad Laboratories beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Bio-Rad Reports First-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Announces Life Science Group Management Changes
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity? ↗
480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. April has been bleak for the market, but some undervalued stocks may be worth... 
Via Benzinga
Topics Stocks
News headline image
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What's Driving Markets Friday? ↗
Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impacting major indices and stocks. 
Via Benzinga
Topics Economy
News headline image
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
10 S&P 500 Stocks With Over 40% Upside Potential: Hidden Gems Or Value Traps? ↗
S&P 500 index surges to new highs, driven by AI, earnings optimism, and Fed rate cuts. Top 10 stocks with significant upside potential for 2024 rally. 
Via Benzinga
Topics Artificial Intelligence Economy Stocks
News headline image
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets ↗
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
News headline image
Black Friday On Wall Street: 10 S&P 500 Stocks Trading At 40%+ Discount From Analysts' Expectations ↗
Several S&P 500 stocks are trading at discounts of over 40% compared to analysts' price targets, offering potential upside, but caution is needed. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.